HopeStage
Back to all studies
RecruitingNCT04781140

Viloxazine or placebo for preschool children with ADHD

About this titleRead the official source — NCT04781140

Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.

Medication studyAges 48–69 monthsUnited States
The study in practice

Understand this study

What is this study about?

Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.

Who could participate?

Listed age limits: 48 months to 69 months.

What will I do during this study?

After screening for up to four weeks, children are randomly assigned to once-daily SPN-812 or placebo (an inactive comparison treatment) for six weeks. The study lasts up to ten weeks in total.

Listed locations
Saraland and 53 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 19, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
286
Sponsor
Supernus Pharmaceuticals, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 48 Months to 69 Months
Official registry ID
NCT04781140
Official title
Show the full official title

A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Recruitment & locations

Currently recruiting

Saraland · Fayetteville · Little Rock

49 more locations
  • Anaheim
  • Encino
  • Garden Grove
  • Imperial
  • Long Beach
  • Newport Beach
  • Centennial
  • Clermont
  • Coral Gables
  • Gainesville
  • Jacksonville
  • Lakeland
  • Miami
  • Orange City
  • Orlando
  • Tamarac
  • Virginia Gardens
  • Winter Park
  • Atlanta
  • Decatur
  • Savannah
  • Evansville
  • Bardstown
  • Owensboro
  • New Orleans
  • Prairieville
  • Baltimore
  • Boston
  • Bloomfield Hills
  • Flowood
  • Las Vegas
  • Berlin
  • Irvington
  • Neptune City
  • New York
  • Durham
  • Cincinnati
  • West Chester
  • Gresham
  • Hershey
  • North Charleston
  • Summerville
  • Memphis
  • Bellaire
  • Dallas
  • Plano
  • The Woodlands
  • Petersburg
  • Richmond

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.

Who is behind this study?

The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including 100mg SPN-812 and Placebo.

Who can participate?

Listed age limits: 48 months to 69 months.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies